Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025

The bone metabolism treatments market generated pharmaceutical revenues of over $12 bn worldwide in 2009. The incidence and prevalence of bone metabolism disorders are on the rise worldwide, in line with an ageing population and improvements in diagnosis. The increasing number of older people offers significant commercial and therapeutic opportunities. The number of osteoporosis and other bone metabolism patients may exceed 400 million by 2020, reports suggest. Governments and other healthcare providers are investing in health education, diagnosis and treatments for those chronic, debilitating - but controllable - disorders, as our new report discusses.

As Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025 shows, this field is important therapeutically and commercially. Which segments of the bone metabolism disorders market will grow fastest in years to come? How will the osteoporosis market cope with patent expiry? What are the therapeutic and commercial trends to watch? How will national markets perform from 2010 to 2025? What will happen to the current leading products and drug classes? Our report covers those and other questions, providing the information that you need.

We predict that the global market for bone metabolism disorder drugs will expand from 2010 onwards, driven by increasing prevalence of disorders among a rising population of older people worldwide. National markets for those products will expand at different rates, as will different treatment forms. The market will depend upon products with superior performance for its success. Our new report shows how technologies that increase clinical effectiveness, safety and ease of use will be important therapeutically and commercially for bone disorders, benefiting stakeholders.

Detailed analysis of the global bone metabolism disorders market

Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of the R&D pipeline and analyses of commercial drivers and restraints, including a SWOT analysis.

There are over 50 tables and figures included, as well as three full interviews with experts - these are totally unique and unavailable anywhere else. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Report Highlights
Companies Listed
Abbott Laboratories
Abiogen Pharma
Acceleron Pharma
American College of Physicians
Amgen
Apotex
Asahi Kasei Pharma
Astellas Pharma
Axxess Pharma
Banyu (subsidiary of Merck & Co.)
Barr Pharmaceuticals
Bayer HealthCare
Bone Care International
Bone Medical
British Geriatrics Society
British Orthopaedic Association
Cedars-Sinai Medical Center, CA, US
Celgene Corporation
Chugai Pharmaceutical Co (part of Roche Group)
Cytochroma
Daiichi Sankyo
Dr. Reddy's Laboratories
EffRx
Eisai
Eli Lilly
Emisphere Technologies
Esteve
European Medicines Agency(EMEA)
Food and Drug Administration (FDA)
Genzyme
Green Cross Corporation
GlaxoSmithKline (GSK)
International Osteoporosis Foundation (IOF)
Ipsen
Japan Tobacco
Kirin Brewery
Leo Pharma
Ligand Pharmaceuticals
Mayo Clinic, MN, US
Merck & Co.
Nordic Bioscience
Novartis
Novo Nordisk
NPS Pharmaceuticals
Nycomed
OMC Clinical Research Center, CA, US
Ono Pharmaceutical
Osteologix
Pfizer
Preventive Services Task Force (USPSTF)
Proctor & Gamble
Proteolix
Radius Health
Ratiopharm
Roche
Sandoz (Novartis)
Sanofi-Aventis
Sanos Bioscience
Schering-Plough
Servier
Shanghai Huadong University
Shire
Sigma (Australia)
STADA Pharmaceuticals
Taisho Pharmaceutical
Takeda Pharmaceutical Company Limited
Teijin Pharma
Teva Pharmaceutical Industries
The American College of Physicians
TransPharma
UCB Pharma
Unigene Laboratories
University of California (UCLA), CA, US
Upsher-Smith Laboratories
Watson Pharmaceuticals
World Health Organization (WHO)
Wyeth (now part of Pfizer)
Zelos Therapeutics
[Cerrar las informaciones del articulo de mercado]

1. Executive Summary
1.1 Bone Metabolism Disorders: Market Review
1.2 Overview of Chapters in this Report
1.3 Research & Analysis Methods

2. Bone Metabolism Disorders: Causes, Effects, Diagnosis and Treatments
2.1 Bone is a Living Tissue
2.1.1 Bone Structure
2.1.2 Bone Remodelling
2.1.3 Regulation of Bone Remodelling
2.1.3.1 Factors Affecting Bone Metabolism
2.1.3.2 Parathyroid Hormone (PTH)
2.1.3.3 Calcitonin
2.1.3.4 Vitamin D/Calcitriol
2.1.3.5 Other Hormones
2.1.3.6 Local Cell Signalling Factors
2.1.3.7 Physical Stress
2.1.4 Bone Growth and Remodelling
2.2 Bone Metabolism Disorders
2.2.1 Osteoporosis
2.2.1.1 Osteoporosis Leads to Bone Fractures
2.2.1.2 Causes of Osteoporosis
2.2.1.3 Osteoporosis Risk Factors
2.2.1.4 Diagnosis of Osteoporosis
2.2.1.5 Osteoporosis Screening
2.2.1.6 Prevalence of Osteoporosis
2.2.1.7 Counting the Cost of Osteoporosis
2.2.2 Paget's Disease of Bone
2.2.2.1 Paget's Disease is a Chronic Skeletal Disorder
2.2.2.2 The Cause of Paget's Disease
2.2.2.3 Diagnosis of Paget's Disease
2.2.2.4 Prevalence of Paget's Disease
2.2.3 Bone Metastases
2.2.4 Primary Hyperparathyroidism
2.2.5 Secondary Hyperparathyroidism and Renal Osteodystrophy
2.3 Treatment of Bone Metabolism Disorders
2.3.1 Bisphosphonates
2.3.2 Vitamin D or K Analogues
2.3.3 Selective Oestrogen-Receptor Modulators (SERMs)
2.3.4 Parathyroid Hormones (PTH)
2.3.5 Calcimimetics
2.3.6 Calcitonins
2.3.7 Strontium Compounds
2.3.8 Calcium and Vitamin D Supplements

3. The World Bone Metabolism Disorders Market, 2010-2025
3.1 The Bone Metabolism Drug Market Will Expand from 2010
3.2 Osteoporosis Dominates the Bone Metabolism Market Currently
3.3 Bisphosphonates Led the Bone Metabolism Market in 2009
3.4 Bisphosphonates Will Gradually Lose Market Share from 2010 to 2025
3.5 Key Industrial Players in the Bone Metabolism Market
3.6 Leading Brands in the Bone Metabolism Market: Forecasts and Discussions
3.6.1 The Top 15 Bone Metabolism Drugs in 2009
3.6.2 Actonel/Optinate Will Fall From Top Position
3.6.3 Zometa/Aclasta/Reclast: Sales Prospects
3.6.4 Bonviva/Boniva/Bondronat: Sales Prospects
3.6.5 Fosamax/Fosamax Plus D: Increasingly Impacted by Generic Competition
3.6.6 Evista: Sales Peaked in 2008
3.6.7 Forteo/Forsteo: Sustained Growth for a Bone Anabolic Agent
3.6.8 Zemplar: Sales Prospects
3.6.9 Sensipar/Mimpara: Amgen’s Calcimimetic
3.6.10 Protelos: Sales Prospects
3.6.11 Hectorol: Sales Prospects
3.6.12 Teiroc/Bonalon: Sales Prospects
3.6.13 Benet: Sales Prospects
3.6.14 Miacalcin/Miacalcic: Sales Prospects
3.6.15 Elcitonin: Sales Prospects
3.6.16 Alfarol (Alfacalcidol, Chugai)
3.6.17 Preotact Has a Limited Market?
3.6.18 Generic Alendronate
3.7 Approvals in the Bone Metabolism Disorders Market in 2009
3.7.1 Fabyln (Lasofoxifene, Pfizer/Ligand)
3.7.2 Conbriza/Viviant (Bazedoxifene, Wyeth/Ligand)

4. SWOT Analysis of the Bone Metabolism Disorders Market
4.1 SWOT Analysis of the Market
4.2 Strengths of the Bone Metabolism Pharmaceutical Sector
4.3 Generic Competition is the Principal Challenge Facing the Bone Metabolism Sector
4.4 Opportunities for the Bone Metabolism Disorders Market
4.5 Threats to the Bone Metabolism Disorders Market
4.5.1 Drug Side-Effect Publicity
4.5.2 Reimbursement for Bone Metabolism Drugs

5. Geographical Profile of the Bone Metabolism Market, 2010-2025
5.1 North America Led the Bone Metabolism Market in 2009
5.2 Leading Bone Metabolism Country Markets, 2009
5.3 Bone Metabolism Market Forecasts for Leading Countries, 2010-2025
5.4 China and India Will Have Highest Growth from 2010-2025

6. The Bone Metabolism Disorders R&D Pipeline
6.1 Strong Pipeline for Bone Metabolism Disorders
6.2 Reformulations and Novel Therapeutic Agents
6.2.1 Pipeline Developments to Improve Formulations
6.2.2 Bone Anabolic Agents in the Pipeline
6.3 RANKL Inhibitors and Cathepsin K Inhibitors
6.4 Key Pipeline Products: Registration Stage
6.4.1 Prolia (Denosumab/ AMG 162) (Amgen)
6.4.1.1 Prolia is an Effective Treatment for Osteoporosis and Bone Metastases
6.4.1.2 Biologics Licence Application (BLA) for Prolia Submitted in 2009
6.4.1.3 Launch of Prolia Expected in H2 2010
6.4.2 Eldecalcitol (ED-71, Chugai)
6.5 Key Pipeline Products: Phase III
6.5.1 Odanacatib (MK 0822, Merck & Co)
6.5.2 EX101 Effervescent Alendronate (EffRx/Nycomed)
6.5.3 SM021 (Salmon Calcitonin, Novartis)
6.6 Key Pipeline Products: Phase II
6.6.1 JTT-305 (Japan Tobacco)
6.6.2 SAN-134 (Sanos Bioscience)
6.6.3 BA058 (PTHrP Analogue, Radius Health/Ipsen)
6.6.4 ONO-5334 (Ono)
6.6.5 BN003/CaPTHymone (Oral PTH, Bone Medical/Axcess)
6.6.6 ViaDerm -hPTH (PTH, TransPharma/Eli Lilly)
6.6.7 Strontium Malonate (Osteologix)
6.6.8 Capsitonin (Oral Calcitonin, Bone Medical)
6.6.9 AMG 785 (CDP-8581) (Amgen/UCB)
6.7 Key Pipeline Products: Phase I
6.7.1 ACE-011 (Acceleron Pharma)

7. Interviews with Experts on Bone Disorders
7.1 Interview with Dr Stuart Silverman, Medical Director of the Osteoporosis Medical Center, OMC Clinical Research Center, CA, US
7.1.1 Unmet Needs in the Osteoporosis Market
7.1.2 New Bone Anabolic Agents
7.1.3 The Difficulties of Developing New Osteoporosis Drugs
7.1.4 Current Pipeline Drugs for Osteoporosis
7.1.5 Decline of Bisphosphonates
7.2 Interview with Dr Matthew Drake, Mayo Clinic, MN, US
7.2.1 Unmet Needs for Osteoporosis Patients
7.2.2 Future Bone Anabolic Agents
7.2.3 Potential in the Late-Stage Osteoporosis Pipeline
7.2.4 Intricacies of Developing New Osteoporosis Drugs
7.2.5 Side-Effects of Established Bone Metabolism Disorder Drugs
7.2.6 The Development of Drugs to Prevent Osteoporosis
7.2.7 Growth Opportunities in the Osteoporosis Market
7.3 Interview with Dr Jasbir Seehra, Chief Scientific Officer, Senior Vice President and Founder, Acceleron Pharma, Inc., MA, US
7.3.1 Unmet Needs in Osteoporosis Patients
7.3.2 On ACE-011 Fulfilling Unmet Needs in the Market
7.3.3 On ACE-011 in Comparison With Current Therapies
7.3.4 Advantages and Disadvantages of ACE-011 Compared with Other Pipeline Drugs

8. Conclusions
8.1 The Bone Metabolism Disorders Market 2010-2025 – What will the Future Hold?
8.2 Growth Drivers for the Bone Metabolism Disorders Market
8.3 Closing Thoughts on the Industry and Market
[Cerrar la tabla de contenidos]

Table 2.1 Hormones Involved in Bone Metabolism
Table 2.2 Worldwide Prevalence of Osteoporosis
Table 2.3 Bone Metabolism Disorder Therapies, 2010
Table 3.1 Bone Metabolism Disorders: World Pharmaceutical Sales, 2009-2025
Table 3.2 Bone Metabolism Disorders: World Sales and Market Shares by Disease Area, 2009
Table 3.3 Bone Metabolism Disorders: World Sales and Market Shares by Drug Class, 2009
Table 3.4 Bisphosphonates: World Sales and Market Shares by Brand, 2009
Table 3.5 Bone Metabolism Disorders: World Sales by Drug Class, 2009-2025
Table 3.6 Bone Metabolism Disorders: World Sales and Market Shares by Manufacturer, 2009
Table 3.7 Leading Bone Metabolism Disorders Brands: World Sales, 2009
Table 3.8 Leading Bone Metabolism Disorders Brands: World Sales, 2009-2025
Table 3.9 Generic Alendronate Manufacturers, 2009
Table 4.1 SWOT Chart for the Bone Metabolism Disorders Sector, 2010
Table 4.2 Expected Patent Expiries in the Bone Metabolism Market
Table 5.1 Bone Metabolism Disorders: World Sales and Market Shares by Geographical Region, 2009
Table 5.2 Leading Bone Metabolism Country Markets: Sales and Market Shares, 2009
Table 5.3 Leading Bone Metabolism Country Markets: Sales, 2009-2025
Table 5.4 Population Aged 65 or Over: US, Japan, China and India, 2009-2025
Table 6.1 Bone Metabolism Disorders: R&D Pipeline, 2010
Table 6.2 Disadvantages of Current Anabolic Bone Agents, 2010
Table 8.1 Leading Bone Metabolism Country Markets: World Market Shares, 2009 and 2025
Figure 2.1 Appearance of Healthy Bone
Figure 2.2 Bone Affected by Osteoporosis
Figure 2.3 Bones Commonly Affected by Paget's Disease
Figure 3.1 Bone Metabolism Disorders: World Pharmaceutical Sales, 2009-2025
Figure 3.2 Bone Metabolism Disorders: World Market Shares by Disease Area, 2009
Figure 3.3 Bone Metabolism Disorders: World Market Shares by Drug Class, 2009
Figure 3.4 Bisphosphonates: World Market Shares by Brand, 2009
Figure 3.5 Bone Metabolism Disorders: World Sales by Drug Class, 2009-2025
Figure 3.6 Bone Metabolism Disorders: World Market Shares by Drug Class, 2015
Figure 3.7 Bone Metabolism Disorders: World Market Shares by Drug Class, 2020
Figure 3.8 Bone Metabolism Disorders: World Market Shares by Drug Class, 2025
Figure 3.9 Bone Metabolism Disorders: World Market Shares by Manufacturer, 2009
Figure 3.10 Leading Bone Metabolism Disorders Brands, 2009
Figure 3.11 Actonel/Optinate: World Sales, 2009-2025
Figure 3.12 Leading Bone Metabolism Brands (Bisphosphonates): World Sales, 2009-2025
Figure 3.13 Zometa/Aclasta/Reclast: World Sales, 2009-2025
Figure 3.14 Bonviva/Boniva/Bondronat: World Sales, 2009-2025
Figure 3.15 Fosamax/Fosamax Plus D: World Sales, 2009-2025
Figure 3.16 Leading Bone Metabolism Brands (Non-Bisphosphonates): World Sales, 2009-2025
Figure 3.17 Evista: World Sales, 2009-2025
Figure 3.18 Forteo/Forsteo: World Sales, 2009-2025
Figure 3.19 Zemplar: World Sales, 2009-2025
Figure 3.20 Sensipar/Mimpara: World Sales, 2009-2025
Figure 3.21 Protelos: World Sales, 2009-2025
Figure 3.22 Hectorol: World Sales, 2009-2025
Figure 5.1 Bone Metabolism Disorders: World Market Shares by Geographical Region, 2009
Figure 5.2 Bone Metabolism Disorders: World Market Shares for Leading Countries, 2009
Figure 5.3 Leading Bone Metabolism Country Markets (Higher Group): Sales, 2009-2025
Figure 5.4 Leading Bone Metabolism Country Markets (Lower Group): Sales, 2009-2025
Figure 5.5 Bone Metabolism Disorders: World Market Shares for Leading Countries, 2015
Figure 5.6 Bone Metabolism Disorders: World Market Shares for Leading Countries, 2020
Figure 5.7 Bone Metabolism Disorders: World Market Shares for Leading Countries, 2025
Figure 8.1 Bone Metabolism Disorders: World Sales, 2009-2025
[Ocultar lista de tablas / figuras]